

Chassieu, 02 June 2021

**ORDINARY AND EXTRAORDINARY GENERAL MEETING TO BE HELD  
ON 24 JUNE 2021  
MODALITIES THROUGH WHICH THE PREPARATORY DOCUMENTS WILL BE MADE  
AVAILABLE**

The General Meeting of Amoéba shareholders, convened on May 27, 2021 at 9 a.m. at the Company's registered office, did not reach the quorum required to vote on the ordinary and extraordinary resolutions.

Consequently, a new Ordinary and Extraordinary Shareholders' Meeting will be held on second call on:

**Thursday 24 June 2021 – 9.00 am  
at the company registered office - 38 Avenue des Frères Montgolfier- 69680 CHASSIEU**

for the purpose of ruling on the same agenda as the first convocation notice, published in the Bulletin des Annonces Légales Obligatoires (BALO) of 10 May 2021.

The notice of the second convocation including the agenda was published in the Bulletin des Annonces légales Obligatoires (BALO) of June 2, 2021. The terms and conditions of participation and voting at the Meeting are set out in this notice.

The documents stipulated by article R.225-83 of the French commercial code are available to shareholders from the moment that the assembly is convened, in line with the applicable regulatory requirements:

- Any registered shareholder can, until the fifth day (inclusive) before the assembly, ask the company to send him these documents. For holders of bearer shares, this right can only be exercised upon presentation of a statement of participation in the accounts of bearer shares held by the authorised intermediary;
- Any shareholder can consult these documents at the company's headquarters during the 15 days preceding the date of the meeting.

**REMINDER**

**VOTE DIRECTLY ONLINE USING VOTACCESS**

As of today, Wednesday, June 2, log on to the website of your financial intermediary dedicated to the management of your AMOEBA shares, with your usual access codes and vote online if you hold your shares in one of the following banks (list of banks offering access to the VOTACCESS platform): Banque Populaire, Banque Postale, BNP Paribas, Bourse Direct, Boursorama, Caisse d'Epargne, Crédit Agricole, Crédit Mutuel, CIC, HSBC, Milleis, Natixis, Société Générale.

#### NEED MORE INFORMATION?

Find all the information you need to vote by post or give proxy to the Chairman on our dedicated page:  
<https://amoeba-nature.com/en/investor/general-assembly/>

We are at your disposal to provide you with any additional information on voting procedures by calling+ 33 (0)1 53 65 68 68 or by email at [amoeba@calyptus.net](mailto:amoeba@calyptus.net)

#### Disclaimer

*In the context of the coronavirus epidemic (COVID-19), the procedures for holding the Shareholders' Meeting may change depending on health and/or legal requirements. Shareholders are invited to regularly consult the section dedicated to the Shareholders' Meeting on the Company's website (<http://www.amoeba-nature.com/Investors/General-assembly>).*

#### About AMOÉBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on Euronext Growth. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on [www.amoeba-nature.com](http://www.amoeba-nature.com).

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

#### Contacts:

##### Amoéba

Valérie FILIATRE

Directeur Général Adjoint

+33 4 26 69 16 00

[v.filiatre@amoeba-nature.com](mailto:v.filiatre@amoeba-nature.com)

##### Calyptus

Relations investisseurs & Presse

Grégory BOSSON / Mathieu CALLEUX

+33 1 53 65 37 90 /91

[amoeba@calyptus.net](mailto:amoeba@calyptus.net)